Artiva Biotherapeutics (NASDAQ:ARTV) Price Target Raised to $40.00

Artiva Biotherapeutics (NASDAQ:ARTV) had its price objective boosted by Cantor Fitzgerald from $10.00 to $40.00 in a research note issued to investors on Monday morning,Benzinga reports. Cantor Fitzgerald currently has an overweight rating on the stock.

A number of other research analysts also recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research report on Friday, April 24th. HC Wainwright raised their target price on shares of Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Wedbush raised their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the company an “outperform” rating in a research report on Monday. Needham & Company LLC reissued a “buy” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research report on Monday, May 4th. Finally, Wall Street Zen raised shares of Artiva Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $39.00.

Artiva Biotherapeutics Stock Performance

NASDAQ ARTV opened at $10.50 on Monday. The company has a market capitalization of $259.56 million, a price-to-earnings ratio of -2.97 and a beta of 2.86. The company’s 50-day simple moving average is $8.00 and its two-hundred day simple moving average is $5.52. Artiva Biotherapeutics has a one year low of $1.47 and a one year high of $14.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Friday, May 8th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.07). Equities analysts expect that Artiva Biotherapeutics will post -2.8 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Ra Capital Management, L.P. acquired 6,510,416 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average price of $11.52 per share, with a total value of $74,999,992.32. Following the transaction, the director directly owned 15,203,995 shares in the company, valued at approximately $175,150,022.40. This represents a 74.89% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 21.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the company. Citadel Advisors LLC grew its position in shares of Artiva Biotherapeutics by 419.3% in the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after buying an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets grew its position in shares of Artiva Biotherapeutics by 14,463.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock worth $340,000 after buying an additional 117,733 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Artiva Biotherapeutics by 46.8% in the 4th quarter. Renaissance Technologies LLC now owns 116,200 shares of the company’s stock worth $498,000 after buying an additional 37,053 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Artiva Biotherapeutics in the 4th quarter worth approximately $341,000. Finally, Jane Street Group LLC purchased a new position in shares of Artiva Biotherapeutics in the 2nd quarter worth approximately $67,000.

Artiva Biotherapeutics News Summary

Here are the key news stories impacting Artiva Biotherapeutics this week:

• Positive Sentiment: Ra Capital Management disclosed a purchase of 6.51 million shares at $11.52 each, a roughly $75 million insider buy that materially increased its stake in Artiva Biotherapeutics. SEC Form 4 filing
• Positive Sentiment: Needham & Company raised its price target on Artiva Biotherapeutics to $41 from $18 and kept a buy rating, implying substantial upside from current levels. Benzinga report
• Positive Sentiment: HC Wainwright reiterated a buy rating and $35 price target while raising several earnings estimates for 2026 and beyond, suggesting improving expectations for the company’s long-term earnings path.
• Positive Sentiment: Additional analyst updates from Cantor Fitzgerald and Wedbush were also described as positive, reinforcing the broader bullish sentiment around ARTV.
• Neutral Sentiment: Some HC Wainwright estimates were mixed, with certain long-term EPS forecasts lowered even as nearer-term projections improved, so the analyst picture is not uniformly optimistic.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.